9-22006148-C-T

Variant summary

Our verdict is Benign. Variant got -7 ACMG points: 0P and 7B. BP4_ModerateBP6BS2

The NM_004936.4(CDKN2B):​c.256G>A​(p.Asp86Asn) variant causes a missense change. The variant allele was found at a frequency of 0.00169 in 1,611,768 control chromosomes in the GnomAD database, including 7 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0012 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0017 ( 7 hom. )

Consequence

CDKN2B
NM_004936.4 missense

Scores

4
11
4

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:1

Conservation

PhyloP100: 4.36
Variant links:
Genes affected
CDKN2B (HGNC:1788): (cyclin dependent kinase inhibitor 2B) This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008]
CDKN2B-AS1 (HGNC:34341): (CDKN2B antisense RNA 1) This gene is located within the CDKN2B-CDKN2A gene cluster at chromosome 9p21. The gene product is a functional RNA molecule that interacts with polycomb repressive complex-1 (PRC1) and -2 (PRC2), leading to epigenetic silencing of other genes in this cluster. This region is a significant genetic susceptibility locus for cardiovascular disease, and has also been linked to a number of other pathologies, including several cancers, intracranial aneurysm, type-2 diabetes, periodontitis, Alzheimer's disease, endometriosis, frailty in the elderly, and glaucoma. Multiple alternatively processed transcript variants have been detected, some of which may take the form of circular RNA molecules (PMID:21151960). [provided by RefSeq, May 2014]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -7 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.119099796).
BP6
Variant 9-22006148-C-T is Benign according to our data. Variant chr9-22006148-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 426555.We mark this variant Likely_benign, oryginal submissions are: {Uncertain_significance=2, Benign=1}.
BS2
High AC in GnomAd4 at 176 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
CDKN2BNM_004936.4 linkuse as main transcriptc.256G>A p.Asp86Asn missense_variant 2/2 ENST00000276925.7
CDKN2B-AS1NR_003529.3 linkuse as main transcriptn.371+10987C>T intron_variant, non_coding_transcript_variant

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
CDKN2BENST00000276925.7 linkuse as main transcriptc.256G>A p.Asp86Asn missense_variant 2/21 NM_004936.4 P1P42772-1
CDKN2B-AS1ENST00000650946.1 linkuse as main transcriptn.29+10987C>T intron_variant, non_coding_transcript_variant

Frequencies

GnomAD3 genomes
AF:
0.00116
AC:
176
AN:
152260
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000654
Gnomad ASJ
AF:
0.00202
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.000470
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00207
Gnomad OTH
AF:
0.00143
GnomAD3 exomes
AF:
0.00120
AC:
291
AN:
242194
Hom.:
0
AF XY:
0.00123
AC XY:
163
AN XY:
132258
show subpopulations
Gnomad AFR exome
AF:
0.000131
Gnomad AMR exome
AF:
0.000466
Gnomad ASJ exome
AF:
0.00142
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000164
Gnomad FIN exome
AF:
0.000655
Gnomad NFE exome
AF:
0.00216
Gnomad OTH exome
AF:
0.00117
GnomAD4 exome
AF:
0.00174
AC:
2542
AN:
1459390
Hom.:
7
Cov.:
31
AF XY:
0.00171
AC XY:
1241
AN XY:
726128
show subpopulations
Gnomad4 AFR exome
AF:
0.000269
Gnomad4 AMR exome
AF:
0.000425
Gnomad4 ASJ exome
AF:
0.00119
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000812
Gnomad4 FIN exome
AF:
0.000583
Gnomad4 NFE exome
AF:
0.00213
Gnomad4 OTH exome
AF:
0.00126
GnomAD4 genome
AF:
0.00116
AC:
176
AN:
152378
Hom.:
0
Cov.:
32
AF XY:
0.00105
AC XY:
78
AN XY:
74518
show subpopulations
Gnomad4 AFR
AF:
0.000240
Gnomad4 AMR
AF:
0.000653
Gnomad4 ASJ
AF:
0.00202
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.000470
Gnomad4 NFE
AF:
0.00207
Gnomad4 OTH
AF:
0.00142
Alfa
AF:
0.00195
Hom.:
1
Bravo
AF:
0.00117
TwinsUK
AF:
0.00135
AC:
5
ALSPAC
AF:
0.00234
AC:
9
ESP6500AA
AF:
0.000228
AC:
1
ESP6500EA
AF:
0.00303
AC:
26
ExAC
AF:
0.00142
AC:
172
EpiCase
AF:
0.00180
EpiControl
AF:
0.00213

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:1
Benign, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenMay 01, 2024CDKN2B: BS1, BS2 -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxApr 12, 2017The D86N variant in the CDKN2B gene has been reported previously as a germline variant in one individual with a metastatic pancreatic endocrine tumor (Lindberg et al., 2008). The D86N variant has also been reported in an individual with primary hyperparathyroidism caused by a sporadic parathyroid adenoma; the D86N variant was present in the germline and accompanied by a loss of the second CDKN2B allele in the tumor sample (Costa-Guda et al., 2013). In addition, the D86N variant was reported as a germline variant in an individual with clear-cell renal cell carcinoma (Jafri et al., 2015). In vitro functional studies of the D86N variant demonstrate impaired CDK6 binding and impaired growth suppressor activity (Costa-Guda et al., 2013; Jafri et al., 2015). The D86N variant is observed in 150/61460 (0.24%) alleles from individuals of European background, in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The D86N variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret D86N as a variant of uncertain significance. -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalJul 31, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.71
BayesDel_addAF
Benign
-0.19
T
BayesDel_noAF
Uncertain
-0.060
CADD
Uncertain
25
DANN
Pathogenic
1.0
DEOGEN2
Uncertain
0.69
D
Eigen
Uncertain
0.51
Eigen_PC
Uncertain
0.52
FATHMM_MKL
Uncertain
0.95
D
LIST_S2
Uncertain
0.95
D
M_CAP
Pathogenic
0.30
D
MetaRNN
Benign
0.12
T
MetaSVM
Uncertain
0.65
D
MutationAssessor
Benign
0.99
L
MutationTaster
Benign
1.0
D;D
PrimateAI
Uncertain
0.75
T
PROVEAN
Pathogenic
-4.7
D
REVEL
Uncertain
0.46
Sift
Uncertain
0.0010
D
Sift4G
Uncertain
0.020
D
Polyphen
1.0
D
Vest4
0.66
MVP
0.98
MPC
1.2
ClinPred
0.15
T
GERP RS
4.8
Varity_R
0.69
gMVP
0.78

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs148421170; hg19: chr9-22006147; COSMIC: COSV52805657; API